Aerovate Therapeutics (AVTE) Competitors $9.00 -0.82 (-8.35%) As of 07/14/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. ELVN, GPCR, CDTX, ARDX, PRAX, PROK, COLL, AKBA, AMPH, and RCUSShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), Cidara Therapeutics (CDTX), Ardelyx (ARDX), Praxis Precision Medicines (PRAX), ProKidney (PROK), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Amphastar Pharmaceuticals (AMPH), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Its Competitors Enliven Therapeutics Structure Therapeutics Cidara Therapeutics Ardelyx Praxis Precision Medicines ProKidney Collegium Pharmaceutical Akebia Therapeutics Amphastar Pharmaceuticals Arcus Biosciences Enliven Therapeutics (NASDAQ:ELVN) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Do institutionals and insiders believe in ELVN or AVTE? 95.1% of Enliven Therapeutics shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, ELVN or AVTE? Enliven Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$89.02M-$1.92-11.28Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-5.29 Does the media refer more to ELVN or AVTE? In the previous week, Enliven Therapeutics had 11 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 11 mentions for Enliven Therapeutics and 0 mentions for Aerovate Therapeutics. Enliven Therapeutics' average media sentiment score of 0.57 beat Aerovate Therapeutics' score of 0.00 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Enliven Therapeutics Positive Aerovate Therapeutics Neutral Which has more volatility and risk, ELVN or AVTE? Enliven Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Is ELVN or AVTE more profitable? Enliven Therapeutics' return on equity of -31.84% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -31.84% -30.09% Aerovate Therapeutics N/A -90.19%-77.47% Do analysts rate ELVN or AVTE? Enliven Therapeutics currently has a consensus price target of $41.20, indicating a potential upside of 90.30%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Enliven Therapeutics is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryEnliven Therapeutics beats Aerovate Therapeutics on 9 of the 13 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$260.87M$724.83M$5.61B$9.29BDividend YieldN/A4.84%4.23%4.03%P/E Ratio-3.011.1828.5419.58Price / SalesN/A25.52429.2495.01Price / CashN/A19.5636.0257.93Price / Book2.276.918.145.54Net Income-$75.52M-$4.17M$3.24B$257.73M7 Day Performance-13.88%1.41%0.18%-0.08%1 Month Performance33.14%1.34%5.96%8.09%1 Year Performance-87.08%7.45%26.24%13.02% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate TherapeuticsN/A$9.00-8.4%N/A-86.5%$260.87MN/A-3.0120High Trading VolumeELVNEnliven Therapeutics2.7955 of 5 stars$23.00+2.4%$41.20+79.1%-13.7%$1.13BN/A-11.9850GPCRStructure Therapeutics2.9038 of 5 stars$19.57+2.9%$76.17+289.2%-56.8%$1.12BN/A-22.49136Positive NewsCDTXCidara Therapeutics4.1779 of 5 stars$55.32+9.5%$57.29+3.6%+311.9%$1.12B$1.27M-1.8890Positive NewsHigh Trading VolumeARDXArdelyx4.0663 of 5 stars$4.61+2.7%$10.89+136.2%-24.4%$1.10B$333.61M-20.9590Analyst RevisionPRAXPraxis Precision Medicines2.2463 of 5 stars$53.60+6.1%$94.11+75.6%+1.8%$1.09B$8.55M-5.00110News CoverageAnalyst RevisionPROKProKidney3.519 of 5 stars$3.69-18.7%$5.67+53.6%+41.0%$1.08B$306K-6.153Trending NewsAnalyst ForecastGap UpHigh Trading VolumeCOLLCollegium Pharmaceutical4.2933 of 5 stars$32.83+1.0%$43.75+33.3%+0.7%$1.05B$631.45M26.91210Buyback AnnouncementAKBAAkebia Therapeutics3.6558 of 5 stars$3.97+1.0%$6.75+70.0%+196.2%$1.04B$160.18M-18.90430AMPHAmphastar Pharmaceuticals4.2953 of 5 stars$21.95+1.3%$32.33+47.3%-45.4%$1.03B$731.97M7.952,028RCUSArcus Biosciences2.3011 of 5 stars$9.66+3.5%$21.29+120.5%-41.5%$1.02B$258M-2.30500 Related Companies and Tools Related Companies Enliven Therapeutics Competitors Structure Therapeutics Competitors Cidara Therapeutics Competitors Ardelyx Competitors Praxis Precision Medicines Competitors ProKidney Competitors Collegium Pharmaceutical Competitors Akebia Therapeutics Competitors Amphastar Pharmaceuticals Competitors Arcus Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts